Cisatracurium Besylate Injection, Solution
Product Images NDC 71288-712

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Cisatracurium Besylate (NDC 71288-712). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Meitheal Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel – Cisatracurium Besylate Injection, Usp – 5 mL Carton (Cis Ht 10mg Carton)

Packaging label for Cisatracurium Besylate Injection, USP, at 10 mg per 5 mL (2 mg per mL) strength, in a 5 mL single-dose vial pack of 10. The label includes a warning about it being a paralyzing agent, states it is for intravenous infusion, and lists Meitheal Pharmaceuticals Inc. as the labeler.*

FDA Label Image

Principal Display Panel – Cisatracurium Besylate Injection, Usp – 5 mL Vial Label (Cis Ht 10mg Vial)

Label for Cisatracurium Besylate Injection, USP 10 mg per 5 mL (2 mg per mL) in a 5 mL single-dose vial. The label indicates it is a paralyzing agent for intravenous injection, with storage instructions to refrigerate at 2° to 8°C and protect from light. Manufactured for Meitheal Pharmaceuticals Inc., Chicago, IL 60631 (USA).*

FDA Label Image

Principal Display Panel – Cisatracurium Besylate Injection, Usp – 20 mL Carton (Cis Ht 200mg Carton)

Packaging label for Cisatracurium Besylate Injection, USP 200 mg per 20 mL (10 mg per mL) by Meitheal Pharmaceuticals Inc. The label highlights the drug strength, intravenous route, and a red warning indicating it is a paralyzing agent for ICU use only. The carton is designed for 10 vials of 20 mL single-dose injections.*

FDA Label Image

Principal Display Panel – Cisatracurium Besylate Injection, Usp – 20 mL Vial Label (Cis Ht 200mg Vial)

Cisatracurium Besylate Injection, USP 200 mg per 20 mL (10 mg per mL) single-dose vial label by Meitheal Pharmaceuticals Inc. The label specifies intravenous use, with warnings for paralysis and ICU use only. Storage instructions indicate refrigeration at 2°C to 8°C with protection from light.*

FDA Label Image

Principal Display Panel – Cisatracurium Besylate Injection, Usp – 10 mL Carton (Cis Ht 20mg Carton)

Carton label for Cisatracurium Besylate Injection, USP, 20 mg per 10 mL (2 mg per mL) solution for intravenous use, manufactured by Meitheal Pharmaceuticals Inc. The label includes dosage warning information, storage instructions, and barcode. The product is presented in a 10 mL vial.*

FDA Label Image

Principal Display Panel – Cisatracurium Besylate Injection, Usp – 10 mL Vial Label (Cis Ht 20mg Vial)

Label for Cisatracurium Besylate Injection, USP, 20 mg per 10 mL (2 mg/mL) intravenous solution. The label highlights a warning that it is a paralyzing agent and states it contains 0.9% benzyl alcohol as a preservative. It is a 10 mL multi-dose vial manufactured by Meitheal Pharmaceuticals Inc., Chicago, IL, with storage instructions and space for lot, expiration, and discard dates.*

FDA Label Image

Figure 1 (Cis Ht Fig1)

A scatter plot chart showing individual data points with two axes labeled HR (Heart Rate) on the vertical axis and MAP (Mean Arterial Pressure) on the horizontal axis, both ranging from -60% to +60%. The data points cluster near the origin, depicting changes in HR and MAP percentages.*

FDA Label Image

Figure 2 (Cis Ht Fig2)

A scatter plot chart displaying data points measuring percent change in heart rate (HR) on the vertical axis against mean arterial pressure (MAP) on the horizontal axis, both axes ranging from -60% to +60%. The plot shows distribution of individual data points centered near the origin.*

FDA Label Image

Structural Formula (Cis Ht Struct)

Chemical structure of Cisatracurium Besylate, showing two quaternary ammonium groups connected by ester linkages and benzyl groups, along with the besylate counterions.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.